Modern systemic therapies for atopic dermatitis Which factors determine the choice of therapy?

For the treatment of moderate to severe atopic dermatitis (AD), two groups of modern systemic therapies with a total of five drugs are currently approved in Germany: biologics (dupilumab, tralokinumab) and small molecules (abrocitinib, baricitinib, upadacitinib). The growing armamentarium of therapy options, especially with more than one drug per substance group, makes it challenging for practitioners to select the appropriate treatment for the individual patient. In this review article, the preconditions and requirements of each drug group as well as the corresponding substances are presented comparatively. On the one hand, direct therapeutic effects on the severity of the disease are considered and, on the other hand, the spectrum of potential adverse drug reactions are discussed. In particular, short- and long-term effects, the safety profile and the patient's concomitant diseases represent key factors for shared decision-making with regard to select the optimum personalized therapy option

Automated summary

This review article presents a comparative analysis of the conditions, requirements, and corresponding substances of biologics and small molecules approved for the treatment of moderate to severe atopic dermatitis in Germany. The study considers the direct therapeutic effects and potential adverse drug reactions, providing insights for the selection of personalized treatment options.